The Dutch government invests in biomedical research through FES. The aim is to stimulate development by facilitating the creation of viable products based on research. UMC Utrecht is involved in several FES initiatives.
TI Pharma Top Institute Pharma (TI Pharma) is a collaborative structure consisting of industrial and academic research teams. TI Pharma conducts groundbreaking, cross-disciplinary research and trains their personnel in improving the efficiency of the entire drug discovery and development process.
Researchers from the UMC Utrecht participate in 18 of the total of 45 projects.
For more information see the link at the bottom of the page.
CTMMThe Center for Translational Molecular Medicine (CTMM is a public-private partnership that comprises universities, academic medical centers, medical technology enterprises and chemical and pharmaceutical companies. CTMM conducts ground-breaking research to develop medical technologies that enable early and precise diagnosis, and design of new and personalized treatments for the main diseases causing mortality and diminished quality of life. "Translating science into better healthcare", is the slogan of CTMM.
At present, researchers from UMC Utrecht are involved in 6 projects in 3 areas:
Cardiovascular diseases
- PREDICCt: Biomarkers for the prediction and early diagnosis of diabetes and diabetes-related cardiovascular complications. (Prof.dr. Van der Schouw, Prof.dr. Grobbee)
- COHFAR: Biomarkers to predict cardiac failure, arythmias, and success of treatment. (Secretary, Prof.dr. Vos, secretary, UMC Utrecht)
- Circulating cells: The natural sensors of plaque and patient destabilization (Prof.dr. Pasterkamp / Prof.dr. de Groot, secretary, UMC Utrecht)
- TRIUMPH: Translational Initiative on Unique and novel strategies for Management of Patients with Heart failure (Prof. dr. Doevendans, Prof.dr. De Windt)
Oncological diseases
- BioChip-based diagnostic and prognostic tests for hematopoietic malignancies (Prof.dr. Coffer, Prof.dr. Burgering)
Neurodegenerative diseases
- Imaging Alzheimer - LeARN: In vivo molecular diagnostics in Alzheimer's Disease (Prof.dr. Luijten)
For more information see the link at the bottom of the page.
BMM
The Biomedical Material Technology Platform (BMM) is a five-year program that aims to build a technology platform and infrastructure for Biomedical Materials and applications. BMM aims to bring together players in academia, research institutes, medical centers and industry to speed up developments by joining forces in a multidisciplinary approach.
At present, researchers from UMC Utrecht are involved in 5 projects in 2 areas:
Cardiovascular diseases
- iValve: Instructive scaffolds for in situ tissue engineering of heart valves and arteries (Prof.dr. van Herwerden)
- PENT: Polymer-enabled neovascularization therapies (Dr. Höfer)
- SMARTCARE: Smart microtissues for cardiac regeneration (Prof. Doevendans, secretary, UMC Utrecht)
Musculoskeletal diseases
- IDiDAS: New early therapies for intervertebral disc diseases. Drug delivery and augmentation through smart polymeric biomaterials (Prof. Dhert/ Dr. Creemers, secretary, UMC Utrecht)
- OAcontrol: Redirecting the management of osteoarthritis through a biomaterial-based intervention (Prof.dr. Dhert)
- NANTICO: Non-adhesive, antimicrobial coatings for biomedical implants
For more information see the link at the bottom of the page.
Pearl String Initiative/ CVA
Each of the 8 Dutch UMC´s will build and coordinate a joint database and biobank for all patients with a specific diagnosis using uniform definitions and storage circumstances. The data and biomaterials will be collected and stored in each UMC, using the regular electronic patient records to store patient data including imaging data and biobanks to store biomaterial and already completed analyses of the biomaterials.
UMC Utrecht is the director for the patient cohort Cerebrovascular Accidents (CVA).
For more information see the link below.